Pink SheetThe Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai
Pink SheetNovo Nordisk and Eli Lilly are succeeding with National Advertising Division challenges of marketing claims for compounded versions of the GLP-1 agonists semaglutide and tirzepatide. In four new NA
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D
In VivoThe phenomenal success of glucagon-like peptide-1 (GLP-1) receptor agonists in treating diabetes and obesity has sparked a wave of clinical investigations into their potential applications far beyond